Federated Hermes, Inc. Pyxis Oncology, Inc. Transaction History
Federated Hermes, Inc.
- $43.9 Billion
- Q1 2025
A detailed history of Federated Hermes, Inc. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,074 shares of PYXS stock, worth $2,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,074Holding current value
$2,530% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
90Shares Held
23.2MCall Options Held
138KPut Options Held
30.9K-
Laurion Capital Management LP New York, NY3.63MShares$4.42 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.49MShares$3.03 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$2.97 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$1.35 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $42.8M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...